Ms. Shivani Wagh, Joint MD, Supriya Lifescience Ltd.

The Union Budget for 2025, with the scrapping of customs duties on 36 life-saving drugs, among others, is a move that is much needed by the pharmaceutical industry, especially for their critical cancer treatments. This will enable essential medicines to reach patients at lower prices while improving access to advanced healthcare solutions. The continued government boost for bulk drug concessions shall further strengthen domestic Active Pharmaceutical Ingredients (API) manufacturing and, therefore, repair dependency on imports in a step toward making India a leading pharmaceutical manufacturer in the world.

At SupriyaLifescience, we see these reforms as a step in the right direction. By creating a more self-reliant pharmaceutical ecosystem, the budget enables companies like ours to scale up production capacities, promote innovation, and ensure the delivery of high-quality and life-saving medicines to those most in need. The emphasis on affordability and accessibility strikes an accord with our direction toward the delivery of essential pharmaceutical solutions in the resolution of the healthcare challenge in India.

Further than pharmaceuticals, the commitment of the government vis-a-vis health infrastructure—Rs 98,311 crore allotted to the sector, increased medical seats, and setting up 200 cancer centers—is certainly a strong message sent on the launch pad of long-term sustainability of health care. These efforts will undoubtedly assist in improving patient care while they shall be laying a much better platform for medical research and innovations.

Overall, Budget 2025 depicts an approach of balanced stimulation of growth. Such steps are welcomed by us at Supriya Lifescience Ltd. towards focusing on supporting the healthcare journey ahead for pharmaceutical solutions for India.